Health Care & Life Sciences » Biotechnology | Xenetic Biosciences Inc.

Xenetic Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,000.00
-
-
3,000.00
7,585.00
15.80
Cost of Goods Sold (COGS) incl. D&A
52.00
88.70
56.10
36.40
179.90
15.80
Gross Income
948.00
88.70
56.10
2,963.60
7,405.10
15.80
SG&A Expense
9,561.40
12,336.10
9,765.90
10,894.20
10,973.90
7,260.50
EBIT
8,613.50
12,424.80
9,822.00
7,930.60
3,568.80
7,276.30
Unusual Expense
-
500.00
2,125.10
45,460.60
-
-
Non Operating Income/Expense
-
1,396.60
295.00
85.40
41.10
24.60
Interest Expense
0.60
4.70
267.00
729.60
1.80
-
Pretax Income
8,579.20
14,307.10
12,507.50
54,206.10
3,595.10
7,300.50
Consolidated Net Income
8,579.20
14,307.10
12,507.50
54,206.10
3,595.10
7,300.50
Net Income
8,579.20
14,307.10
12,507.50
54,206.10
3,595.10
7,300.50
Net Income After Extraordinaries
8,579.20
14,307.10
12,507.50
54,206.10
3,595.10
7,300.50
Net Income Available to Common
8,579.20
14,307.10
12,507.50
58,241.40
3,595.10
7,300.50
EPS (Basic)
23.63
3.47
2.97
7.84
0.41
9.66
Basic Shares Outstanding
363.10
4,118.10
4,254.50
7,430.60
8,665.80
755.90
EPS (Diluted)
23.63
3.47
2.94
7.84
0.41
9.66
Diluted Shares Outstanding
363.10
4,118.10
4,254.50
7,430.60
8,665.80
755.90
EBITDA
8,561.40
12,336.10
9,765.90
7,894.20
3,545.00
7,260.50
Non-Operating Interest Income
34.90
19.00
1.70
0.00
16.50
0.50
Preferred Dividends
-
-
-
4,035.30
-
-

About Xenetic Biosciences

View Profile
Address
40 Speen Street
Framingham Massachusetts 01701
United States
Employees -
Website http://www.xeneticbio.com
Updated 07/08/2019
Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties.